Clinical characteristics and presence of antiphospholipid antibodies (anticardiolipin-β2GP-1) cerebrospinal fluid and serum of in a series of patients with multiple sclerosis in Mexico
Características clínicas y anticuerpos antifosfolipídicos (anticardiolipina-β2GP-1) en líquido cefalorraquídeo y suero en una muestra de pacientes con esclerosis múltiple en México
Read
1763
Timeswas read the article
872
Total PDF
891
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 18 | 9 | 27 |
| 2025 11 | 29 | 43 | 72 |
| 2025 10 | 15 | 23 | 38 |
| 2025 9 | 12 | 26 | 38 |
| 2025 8 | 15 | 18 | 33 |
| 2025 7 | 25 | 13 | 38 |
| 2025 6 | 15 | 1 | 16 |
| 2025 5 | 19 | 4 | 23 |
| 2025 4 | 17 | 9 | 26 |
| 2025 3 | 20 | 7 | 27 |
| 2025 2 | 16 | 2 | 18 |
| 2025 1 | 13 | 3 | 16 |
| 2024 12 | 16 | 7 | 23 |
| 2024 11 | 13 | 5 | 18 |
| 2024 10 | 9 | 2 | 11 |
| 2024 9 | 10 | 9 | 19 |
| 2024 8 | 12 | 2 | 14 |
| 2024 7 | 12 | 8 | 20 |
| 2024 6 | 5 | 5 | 10 |
| 2024 5 | 8 | 14 | 22 |
| 2024 4 | 7 | 9 | 16 |
| 2024 3 | 17 | 13 | 30 |
| 2024 2 | 16 | 8 | 24 |
| 2024 1 | 8 | 5 | 13 |
| 2023 12 | 11 | 13 | 24 |
| 2023 11 | 6 | 8 | 14 |
| 2023 10 | 22 | 7 | 29 |
| 2023 9 | 7 | 11 | 18 |
| 2023 8 | 8 | 7 | 15 |
| 2023 7 | 15 | 45 | 60 |
| 2023 6 | 9 | 21 | 30 |
| 2023 5 | 6 | 7 | 13 |
| 2023 4 | 3 | 3 | 6 |
| 2023 3 | 4 | 0 | 4 |
| 2023 2 | 5 | 4 | 9 |
| 2023 1 | 6 | 4 | 10 |
| 2022 12 | 9 | 5 | 14 |
| 2022 11 | 30 | 18 | 48 |
| 2022 10 | 10 | 13 | 23 |
| 2022 9 | 5 | 6 | 11 |
| 2022 8 | 12 | 13 | 25 |
| 2022 7 | 5 | 6 | 11 |
| 2022 6 | 11 | 6 | 17 |
| 2022 5 | 8 | 11 | 19 |
| 2022 4 | 20 | 14 | 34 |
| 2022 3 | 8 | 10 | 18 |
| 2022 2 | 6 | 6 | 12 |
| 2022 1 | 6 | 6 | 12 |
| 2021 12 | 3 | 13 | 16 |
| 2021 11 | 5 | 4 | 9 |
| 2021 10 | 11 | 20 | 31 |
| 2021 9 | 4 | 7 | 11 |
| 2021 8 | 7 | 12 | 19 |
| 2021 7 | 7 | 10 | 17 |
| 2021 6 | 10 | 22 | 32 |
| 2021 5 | 12 | 9 | 21 |
| 2021 4 | 18 | 20 | 38 |
| 2021 3 | 13 | 8 | 21 |
| 2021 2 | 13 | 11 | 24 |
| 2021 1 | 9 | 11 | 20 |
| 2020 12 | 10 | 9 | 19 |
| 2020 11 | 10 | 8 | 18 |
| 2020 10 | 10 | 6 | 16 |
| 2020 9 | 7 | 6 | 13 |
| 2020 8 | 7 | 4 | 11 |
| 2020 7 | 5 | 3 | 8 |
| 2020 6 | 5 | 4 | 9 |
| 2020 5 | 3 | 9 | 12 |
| 2020 4 | 5 | 3 | 8 |
| 2020 3 | 4 | 2 | 6 |
| 2020 2 | 6 | 6 | 12 |
| 2020 1 | 9 | 5 | 14 |
| 2019 12 | 11 | 8 | 19 |
| 2019 11 | 4 | 9 | 13 |
| 2019 10 | 5 | 2 | 7 |
| 2019 9 | 8 | 4 | 12 |
| 2019 7 | 4 | 4 | 8 |
| 2019 6 | 5 | 7 | 12 |
| 2019 5 | 24 | 25 | 49 |
| 2019 4 | 10 | 23 | 33 |
| 2019 3 | 1 | 4 | 5 |
| 2019 2 | 3 | 7 | 10 |
| 2019 1 | 1 | 1 | 2 |
| 2018 12 | 0 | 0 | 0 |
| 2018 11 | 2 | 1 | 3 |
| 2018 10 | 3 | 2 | 5 |
| 2018 9 | 2 | 5 | 7 |
| 2018 8 | 0 | 1 | 1 |
| 2018 7 | 0 | 1 | 1 |
| 2018 6 | 2 | 1 | 3 |
| 2018 5 | 4 | 3 | 7 |
| 2018 4 | 2 | 4 | 6 |
| 2018 2 | 0 | 2 | 2 |
| 2018 1 | 1 | 1 | 2 |
| 2017 12 | 0 | 1 | 1 |
| 2017 11 | 1 | 1 | 2 |
| 2017 10 | 2 | 1 | 3 |
| 2017 9 | 0 | 4 | 4 |
| 2017 8 | 2 | 2 | 4 |
| 2017 7 | 2 | 1 | 3 |
| 2017 6 | 0 | 9 | 9 |
| 2017 5 | 2 | 3 | 5 |
| 2017 4 | 7 | 4 | 11 |
| 2017 3 | 3 | 18 | 21 |
| 2017 2 | 1 | 6 | 7 |
| 2017 1 | 1 | 0 | 1 |
| 2016 12 | 2 | 1 | 3 |
| 2016 10 | 1 | 4 | 5 |
| 2016 9 | 2 | 0 | 2 |
| 2016 7 | 1 | 1 | 2 |
Show all
